Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F16%3AN0000095" target="_blank" >RIV/00064190:_____/16:N0000095 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1097/HJH.0000000000000853" target="_blank" >http://dx.doi.org/10.1097/HJH.0000000000000853</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1097/HJH.0000000000000853" target="_blank" >10.1097/HJH.0000000000000853</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke

Popis výsledku v původním jazyce

All major recent guidelines on hypertension management acknowledge that evidence from randomized controlled trials (RCTs) is scanty and controversial about the levels to which blood pressure (BP) should be brought by antihypertensive treatment, in both primary and secondary prevention. Although observational studies have shown that there isa direct relationship between SBP and DBP and majorcardiovascular events [both stroke and coronary heart dis-ease (CHD) events] down to 115 mmHg SBP and 75 mmHgDBP [4], the numerous randomized trials that have dem-onstrated the benefits of BP lowering have very rarelybrought SBP below 130 mmHg, and in most RCTs activetreatment achieved SBP values either between 140 and150 mmHg or a few mmHg below 140 mmHg [1]. Datasuggesting that risk of cardiovascular disease events maybe less effectively prevented when SBP (or DBP) is loweredbelow a given level (so called J-shaped curve) can only beconsidered hypothesis raising, as the type of analysis used(plotting incident outcomes against achieved BP independ-ently of the randomized group) is an analysis of observa-tional data, even if data are collected within a randomizedtrial.

Název v anglickém jazyce

Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke

Popis výsledku anglicky

All major recent guidelines on hypertension management acknowledge that evidence from randomized controlled trials (RCTs) is scanty and controversial about the levels to which blood pressure (BP) should be brought by antihypertensive treatment, in both primary and secondary prevention. Although observational studies have shown that there isa direct relationship between SBP and DBP and majorcardiovascular events [both stroke and coronary heart dis-ease (CHD) events] down to 115 mmHg SBP and 75 mmHgDBP [4], the numerous randomized trials that have dem-onstrated the benefits of BP lowering have very rarelybrought SBP below 130 mmHg, and in most RCTs activetreatment achieved SBP values either between 140 and150 mmHg or a few mmHg below 140 mmHg [1]. Datasuggesting that risk of cardiovascular disease events maybe less effectively prevented when SBP (or DBP) is loweredbelow a given level (so called J-shaped curve) can only beconsidered hypothesis raising, as the type of analysis used(plotting incident outcomes against achieved BP independ-ently of the randomized group) is an analysis of observa-tional data, even if data are collected within a randomizedtrial.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

JOURNAL OF HYPERTENSION

ISSN

0263-6352

e-ISSN

—

Svazek periodika

34

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

3

Strana od-do

393-396

Kód UT WoS článku

000369428100003

EID výsledku v databázi Scopus

2-s2.0-84957543144